Pulmatrix (PULM) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulmatrix is the larger company by market cap ($5.4 million vs $4.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | PULM | XTLB |
|---|---|---|
| Share price | $1.49 | $1.98 |
| Market cap | $5.44M | $4.87M |
| 1-day change | +4.20% | -1.98% |
| EPS (TTM) | $-1.10 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.24 | $7.44 |
| 52-week low | $1.16 | $1.98 |
| Distance from 52-week high | -71.54% | -73.39% |
| Average volume | 24.96K | 8.18K |
| Shares outstanding | 3.65M | 2.46M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
PULM vs XTLB FAQ
Which is bigger, Pulmatrix or XTL Biopharmaceuticals?
Pulmatrix (PULM) is larger, with a market capitalization of $5.44M compared with $4.87M for XTL Biopharmaceuticals (XTLB).
Are Pulmatrix and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.